#Novartis' oral #BTKinhibitor remibrutinib has shown efficacy in a pair of #phase3 trials in #relapsingmultiplesclerosis (RMS), setting up marketing applications and boosting the drug's blockbuster credentials.
pharmaphorum.com/news/novarti...
pharmaphorum.com/news/novarti...
September 1, 2026 at 1:56 PM
#Novartis' oral #BTKinhibitor remibrutinib has shown efficacy in a pair of #phase3 trials in #relapsingmultiplesclerosis (RMS), setting up marketing applications and boosting the drug's blockbuster credentials.
pharmaphorum.com/news/novarti...
pharmaphorum.com/news/novarti...
#Cenrifki #SPMS #multiplesclerosis #relapsingmultiplesclerosis #Sanofi #disabilitytargetingmedicine #nrSPMS #disabilityprogression #EMA #CHMP #HERCULESstudy #MSrelateddisability #brainpenetrantBrutonstyrosinekinaseinhibitor #smoulderingneuroinflammation #SPMSwithoutrelapses
zurl.co/GD1h3
zurl.co/GD1h3
Cenrifki approved in EU for secondary progressive multiple sclerosis - PharmaTimes
Sanofi therapy becomes first disability‑targeting medicine for nrSPMS
pharmatimes.com
June 23, 2026 at 12:43 PM